We have recently demonstrated that the pyrazolopyrimidines PP1 and PP2 and the 4-anilinoquinazoline ZD6474 display a strong inhibitory activity (IC 50 p100 nM) towards constitutively active oncogenic RET kinases. Here, we show that most oncogenic MEN2-associated RET kinase mutants are highly susceptible to PP1, PP2 and ZD6474 inhibition. In contrast, MEN2-associated swap of bulky hydrophobic leucine or methionine residues for valine 804 in the RET kinase domain causes resistance to the three compounds. Substitution of valine 804 with the small amino-acid glycine renders the RET kinase even more susceptible to inhibition (ZD6474 IC 50 : 20 nM) than the wild-type kinase. Our data identify valine 804 of RET as a structural determinant mediating resistance to pyrazolopyrimidines and 4-anilinoquinazolines.
Introduction
RET is a transmembrane tyrosine kinase participating in a cell-surface protein complex that binds the glial derived neurotrophic factor (GDNF) family neurotrophins (Manie et al., 2001) . Germline point mutations in RET cause three related dominantly inherited cancer syndromes: multiple endocrine neoplasia type 2A (MEN2A), 2B (MEN2B) and Familial Medullary Thyroid Carcinoma (FMTC) (Online Mendelian Inheritance in Men, OMIM: #171400). MEN2 patients are invariably affected by Medullary Thyroid Carcinoma (MTC), a malignant tumor arising from calcitoninsecreting C cells of the thyroid (Sherman, 2003) . Additional features can be present in MEN2A (pheochromocytoma and parathyroid adenoma) and MEN2B (pheochromocytoma, mucosal neuroma and ganglioneuroma of the intestine) (Brandi et al., 2001) .
Most MEN2B patients carry the M918T substitution in a domain of the RET kinase, the P þ 1 loop, in strict proximity to the activation loop, while only a small fraction of them harbor the A883F substitution. The majority of MEN2A and FMTC mutations affects one cysteine of the extracellular cysteine-rich domain of RET. Less frequently, FMTC is associated to changes in the N-terminal (E768D, L790F, Y791F, V804L, V804M) or C-terminal (S891A) lobe of the RET kinase. Somatic mutations of V804, M918 and E768 are frequently found in sporadic MTC, as well (Bolino et al., 1995; Ponder, 1999) .
MEN2-associated RET mutations have a gain of function effect, promoting ligand-independent activation of the kinase. This occurs through different mechanisms depending on the location of the aminoacid change. Extracellular cysteine mutants display constitutive kinase activity consequent to disulfidebonds stabilized ligand-independent dimerization (Asai et al., 1995; Santoro et al., 1995; Carlomagno et al., 1997; Ito et al., 1997; Chappuis-Flament et al., 1998) . RET activation by mutations targeting the intracellular domain is less understood (Santoro et al., 1995; Pasini et al., 1997; Iwashita et al., 1999) . Likely, these mutations modify the structure of the kinase switching-on its enzymatic function. In the case of the M918T mutation, a change in substrate specificity has also been proposed (Santoro et al., 1995; Songyang et al., 1995) .
Oncogenic activation of RET can also result from chromosomal inversions or translocations in papillary thyroid carcinomas that cause the recombination of the RET TK to heterologous genes (RET/PTC oncogenes) (Fagin, 2002) .
Targeting the enzymatic activity of tyrosine kinases by small molecule inhibitors is a promising strategy in human cancer therapy (Zwick et al., 2002) . Several molecules have been successfully used in clinical trials and one of them, STI571 (imatinib mesylate or Gleevec), has been approved for treatment of diseases carrying c-KIT point mutations (Gastrontestinal Stromal Tumors) Joensuu et al., 2002) or platelet-derived growth factor receptor (PDGFR) rearrangements (Apperley et al., 2002; Sawyers, 2002a; Cools et al., 2003) . STI571 is now a standard for the treatment of BCR-ABL positive chronic myeloid leukaemia (CML) (Druker et al., 1996 (Druker et al., , 2001 Sawyers et al., 2002b) . However, STI571 treated CMLs often develop resistance to the drug and relapse occurs. Selection of clones with mutations targeting residues that are important for the binding of BCR-ABL to STI571 is one important mechanism of resistance. Among the most prevalent resistance-causing mutations is the substitution of T315 in the BCR-ABL kinase with isoleucine (Schindler et al., 2000) . It remains unclear whether resistance-causing mutations occur under treatment or rather can be pre-existing and be selected by the treatment.
We have identified three tyrosine kinase inhibitors, the pyrazolopyrimidines PP1 and PP2 and the 4-anilinoquinazoline ZD6474, with a strong activity towards RET kinase (IC 50 p100 nM) (Carlomagno et al., 2002a (Carlomagno et al., , b, 2003 . PP1 and PP2 are inhibitors of SRC and SRC-like kinases (Hanke et al., 1996) , while ZD6474 is a powerful inhibitor of the VEGF receptor kinase KDR with additional activity against EGFR (Wedge et al., 2002) . The three compounds are able to block enzymatic activity of RET/C634R and RET/ M918T point mutants and of RET/PTC chimeric oncoproteins, resulting in the efficient inhibition of their tumorigenic potential (Carlomagno et al., 2002a (Carlomagno et al., , b, 2003 .
Understanding mechanism of resistance can help to better design small molecule inhibitors to target oncogenic kinases and better select patients to be treated. Here we have screened a panel of pointmutations targeting the RET kinase domain in familial and sporadic medullary thyroid carcinomas for susceptibility to PP1, PP2 and ZD6474. We show that two naturally occurring mutations of valine 804 of RET cause resistance to the three compounds, thereby identifying valine 804 as a key structural determinant of RET response to small molecule kinase inhibitors.
Results

Inhibition of RET/MEN2 tyrosine kinase domain mutants in living cells
To test the activity of PP1, PP2 and ZD6474 towards RET/MEN2 oncoproteins carrying amino-acid substitutions in the kinase domain, we transiently transfected HEK293 cells with pBABE-based vectors encoding RET/E768D, RET/L790F, RET/Y791F, RET/V804L, RET/V804M, RET/S891A and RET/A883F cDNAs ( Figure 1a ). As controls, we used RET/C634R and RET/M918T constructs, known to be efficiently inhibited by the three compounds. Before harvesting, cells were treated for 2 h with vehicle, 0.5 and 5.0 mM PP1, PP2 or ZD6474 and then lysed. To determine phosphorylation status, proteins were immunoblotted with phosphorylation-specific anti-RET antibodies, able to recognize RET proteins only when phosphorylated on tyrosine 1062 (anti-pY1062) (Figure 1b, c Manie et al., 2001) . Tyrosine 905 maps in the activation loop of the kinase, its phosphorylation stabilizing the active conformation of the enzyme (Iwashita et al., 1996) . Figure 1 shows that according to their oncogenicity, all the RET mutants exerted ligand-independent autophosphorylation. Most of the mutants (RET/ E768D, RET/L790F, RET/Y791F, RET/S891A and RET/A883F) showed a sensitivity profile to the three compounds very similar to that of RET/C634R and RET/M918T (Figure 1b) . Instead, mutations substituting valine 804 either to leucine or to methionine (V804L and V804M) rendered the RET kinase significantly resistant to PP1, PP2 and ZD6474: virtually no inhibition was detected at 0.5 mM and only a modest effect was seen at 5.0 mM (Figure 1c) . Likely, the bulkier hydrophobic side chains of leucine and methionine sterically interferes with the binding of the inhibitors at the nucleotide binding site of RET.
Resistance to inhibition of valine 804 RET mutants in vitro
To further evaluate V804 mutants resistance to PP1, PP2 and ZD6474, we measured their intrinsic catalytic activity by an in vitro phosphorylation assay. We used immunoprecipitated RET proteins and the synthetic peptide poly-(L-glutamic acid-L-tyrosine) (poly-GT) as a substrate. The assay was performed in the presence of different concentrations of PP1 and ZD6474. As shown in Figure 2a , b, while RET/C634R responded very efficiently to PP1 and ZD6474, RET/V804L and RET/ V804M showed a marked increase of residual activity upon treatment with both compounds. V804 mutant kinase activity was resistant to PP2, as well (not shown). A dose-response experiment was performed with ZD6474. IC 50 for both RET/V804 mutants (5.0 mM) was 50-fold higher compared to RET/C634R kinase (100 nM) ( Figure 2c ).
ZD6474 effects on mitogenic activity and signalling of V804 mutants
RET/MEN2 mutants cause morphological transformation and stimulate proliferation of immortalized fibroblasts (Santoro et al., 1995; Pasini et al., 1997; Iwashita et al., 1999) . To verify whether the resistance of V804 mutated RET kinases to pharmacological inhibition had any impact on drug-induced reversion of the transformed phenotype, we treated RAT1 fibroblasts transformed by RET/C634R, RET/M918T, RET/V804M or RET/V804L with 5.0 mM ZD6474 for 24 h and analysed the morphological changes induced by the drug. We restricted this analysis to ZD6474 since it is already in clinical trials (Wedge et al., 2002) . Already at 1.0 mM, ZD6474 caused a complete morphological reversion of RET/C634R-and RET/M918T-transformed cells while To verify whether the resistance of V804 mutated RET kinases to pharmacological inhibition was also translated in the resistance of transformed cells to the growth inhibitory properties of the compounds, we measured ZD6474 effects on the growth rate of RAT1 fibroblasts stably transformed by RET/C634R, RET/ V804M or RET/V804L. Growth curves reported in Figure 4a demonstrate that ZD6474 strongly reduced RAT1-RET/C634R cell growth, already at 1.0 mM, while, at this dose, it had negligible effects on cells expressing valine 804 mutants. Moreover, RET/C634R cell growth was completely blocked by 5.0 mM of the drug, while cells expressing valine 804 mutants were still cycling although at a low rate. Overall, the effects of V804 mutations on the resistance of the RET kinase to the drugs appeared more dramatic than those on RETmediated mitogenic effects. Disagreement between antiproliferative effects in vivo and kinase inhibition in vitro had been already described for other kinase inhibitors and might be attributable to the different ATP concentrations in the test tube and in intact cells or to pleiotropic activity of the drug on multiple pathways in living cells (Blencke et al., 2003) .
Upon oncogenic activation, Grb2 recruitment to tyrosine 1062 couples RET to the activation of the Ras/mitogen-activated protein kinase (MAPK) cascade (reviewed in Manie et al., 2001) . To validate the results showed above, as a read-out of RET mitogenic signalling we analysed MAPK activation extent. In particular, we measured the capability of ZD6474 to obstruct RET-mediated activation of ERK1 and ERK2, determined by immunoblot with phosphospecific antibodies. Mutations of valine 804 resulted in a several-fold reduction of RET signalling inhibition by ZD6474 (Figure 4b ).
RET/V804G mutant sensitivity to PP1 and ZD6474
Valine 804 in RET corresponds to threonine 315 in ABL, a residue that is located at a hydrophobic cavity near the nucleotide binding site and that is implicated in resistance to STI571 (Schindler et al., 2000; Gorre et al., 2001; La Rosee et al., 2002; Nagar et al., 2002; Shah et al., 2002) (Figure 5a ). Furthermore, V804 in RET and T315 in ABL correspond to T338 residue in SRC. Mutation of this threonine to bulky residues decreased SRC sensitivity to PP1, while substitution with a glycine resulted in a sharp decrease of the IC 50 (Bishop et al., . Thus, we reasoned that the steric indrance determined by methionine or leucine in the two spontaneous RET mutants (V804M or V804L) could be the cause of RET resistance to both pyrazolopyrimidines and anilinoquinazolines. To prove this, we substituted RET V804 with a glycine (the smallest amino acid) in the context of a constitutively active RET/C634R mutant. Initially, we tested if the V804G mutation changed the enzymatic and/or transforming activity of RET/C634R. Induction of transformed foci in NIH3T3 fibroblasts by RET/C634R-V804G was slightly (two-fold) reduced in comparison to RET/ C634R (Figure 5b) . Consistently, the kinase activity of RET/C634R-V804G, at three different ATP concentrations (10, 100 and 500 mM), was mildly decreased compared to RET/C634R (Figure 5c ). This is consistent with previous findings showing that, in other kinases, the corresponding mutation modestly increased K m for ATP (Bishop et al., 2000) . Subsequently, HEK293 cells were transiently transfected with RET/C634R or RET/C634R-V804G and treated with low doses (20, 50 or 100 nM) of PP1 or ZD6474 for 2 h. Protein lysates were immunoblotted with anti-pY1062 antibody to check RET phosphorylation levels in vivo. As shown in Figure 5d , the RET/C634R-V804G mutant was significantly more sensitive to the two compounds than wild-type RET/C634R. To obtain a quantitative estimate of the effects of V804G mutation, we measured ZD6474 IC 50 of RET/C634R/V804G by the in vitro poly-GT kinase assay. Consistent with in vivo data, RET/C634R IC 50 was decreased by five-fold when valine 804 was changed to a glycine (Figure 5e ). In vitro poly-GT phosphorylation assay: protein extracts were immunoprecipitated with anti-RET and subjected to a kinase assay with poly-GT as a synthetic substrate, [g-32 P]ATP, and PP1 or ZD6474 at the indicated concentrations. The phosphorylated poly-GT was spotted on 3MM Whatman paper and counted by scintillation. The results of four independent experiments were averaged and presented as residual poly-GT phosphorylation levels compared with the control (DMSO). Standard deviations are shown. (c) The IC 50 of ZD6474 for RET/C634R, RET/V804L or RET/V804M was measured by the poly-GT phosphorylation assay, using decreasing amounts of ZD6474 from 50.0 to 0.05 mM. The results of four independent experiments were averaged. Deviations were less than 20% of the mean Figure 3 The indicated cell lines were treated for 24 h with DMSO, 1.0 or 5.0 mM ZD6474. Cells were photographed by using a phase-contrast light microscope (magnification Â 150)
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Discussion
Here we demonstrate that valine 804, mapping in the V Hanks domain of the N-terminal lobe of the RET kinase, is a structural determinant of sensitivity to different classes of small molecule inhibitors. Thus, RET resistance to enzymatic inhibition can be induced by naturally occurring oncogenic mutations (V804L and V804M), which change valine 804 to amino acids with longer hydrophobic side chains like leucine or methionine.
Our data integrate observations made on other tyrosine kinases to demonstrate that one specific position in several kinases is critical for kinase inhibition by small molecular weight inhibitors. Indeed, in SRC the nature of amino acid (position 338), corresponding to RET V804, is crucial for sensitivity to PP1 and PP2. SRC mutants that carry methionine or isoleucine in that position are resistant to PP1 and PP2, while a glycine in that position increases inhibition (Bishop et al., 2000) . The corresponding residue in the EGFR kinase (T766) (Figure 5a ) influences sensitivity to PD153035, a 4-anilinoquinazoline like ZD6474 (Blencke et al., 2003) .
Since ZD6474 has inhibitory properties also against EGFR (Ciardiello et al., 2003) , it is conceivable that T766 EGFR mutants are resistant to ZD6474 as well. Finally, the corresponding amino acid in ABL, threonine 315, mediates sensitivity to STI571 (Schindler et al., 2000; Gorre et al., 2001; La Rosee et al., 2002; Nagar et al., 2002; Shah et al., 2002) . Crystal structures have shown that inhibitor moieties extend into a hydrophobic cavity of the ATP-binding site that is not occupied by the ATP itself. The residues mapping in position corresponding to RET V804 lie in this cavity. Likely, the presence of space-filling amino acids in that position abrogates efficient inhibitor binding. To formally prove this possibility, we have inserted a glycine in position 804 of RET. The Val804Gly mutation strongly increased RET sensitivity to PP1 and ZD6474.
A peculiar feature of the RET system described here is that resistance-causing mutations are not selected during treatment (like in the case of BCR-ABL). Rather they are spontaneously occurring at the germline or somatic level, in FMTC or sporadic MTC respectively, and cause constitutive activation of RET and increased signalling capacity (Pasini et al., 1997; Iwashita et al., Valine 804 in the RET confer resistance to kinase inhibitors F Carlomagno et al 1999). Therefore, V804M and V804L, at the same time, activate the ligand-independent function of the RET kinase and mediate resistance to inhibitory compounds. This implies that in the case of RET resistance can also pre-exist to the treatment. V804 mutations are found in about 2% of MEN2 carriers as well as in sporadic medullary thyroid carcinomas (Machens et al., 2003) . Familial cases have quite an aggressive potential and several studies described a tendency of the tumor to early onset and invasive behavior (Frohnauer and Decker, 2000) . In addition, V804 mutations can be found in combination with other RET point-mutations on different (Lombardo et al., 2002) or the same RET allele. In particular, Bartsch et al. (2000) described an FMTC kindred carrying a double RET mutation (V804M and R844L), Kasprzak et al. (2001) reported an FMTC family carrying the double V804M and V778I mutation, Menko et al. (2002) described a MEN2B-like family carrying a double V804M and S904C mutation and Iwashita et al. (2000) described another MEN2B family carrying a double V804M-Y806C mutation. Intriguingly, this RET V804M-Y806C mutant exerted an eight-to 13-fold higher transforming activity than that of single RET mutants. Based on our findings, it could be hypothesized that a second hit targeting V804 in an otherwise mutated RET allele could not only cause potentiation of RET oncogenic activity but also resistance formation.
In conclusion, our data support the notion that human cancers sustaining oncogenic mutations of RET may be treatable with pyrazolopyrimidines and 4-anilinoquinazolines. ZD6474 is currently under Phase II clinical trial as an antiangiogenic compound. It is envisaged that a clinical trial for MTC sustained by RET mutations will be initiated soon. In the light of our findings, V804 mutation positive tumors are expected to display primary resistance to ZD6474. It is also conceivable that the RET/V804 mutation could also play a role in acquisition of secondary resistance, so that, upon treatment, a tumor originally negative for the mutation can select clones carrying the RET/V804 substitution and therefore no longer respond to the therapy.
Materials and methods
Compounds
ZD6474 was kindly provided by AstraZeneca (Pharmaceuticals, Macclesfield, UK). PP1 and PP2 were purchased from Alexis (San Diego, CA, USA). Stock solutions (50 mM) were made in 100% DMSO and diluted with culture media or kinase buffer before use. Culture media or kinase buffer containing an equivalent DMSO concentration served as vehicle controls.
Cell culture
Mutations C634R, M918T, A883F, E768D, L790F, Y791F, V804L, V804M and S891A were introduced in RET-9 cDNA, encoding the short isoform of RET protein, cloned in the pBABE expression vector (Pasini et al., 1997) . The V804G mutation was inserted by site-directed mutagenesis in the pBABE RET/C634R construct (pBABE RET/C634R-V804G). All the mutations were confirmed by double-strand DNA sequencing. HEK293 cells were from American Type Culture Collection (ATCC, Manassas, VA, USA) and were grown in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal calf serum (GIBCO, Paisley, PA, USA). Transient transfections were carried out with the lipofectamine reagent according to the manufacturer's instructions (GIBCO). Cells were seeded at a density of 1.5 Â 10 6 /dish the day before transfection, transfected with 5 mg of DNA and harvested 48 h later. Parental RAT1 cells and RAT1 transformed by RET/C634R, RET/V804L and RET/V804M were cultured in DMEM supplemented with 10% fetal calf serum, 2 mM L-glutamine and 100 U/ml penicillin-streptomycin (GIB-CO). NIH3T3 fibroblasts were grown in DMEM (GIBCO) containing 5% calf serum (GIBCO).
Immunoblotting
Protein lysates were prepared according to standard procedures. Cells were lysed in a buffer containing 50 mM N-2-hydroxyethylpiperazine-N 0 -2-ethanesulfonic acid (HEPES; pH 7.5), 1% (vol/vol) Triton X-100, 150 mM NaCl, 5 mM EGTA, 50 mM NaF, 20 mM sodium pyrophosphate, 1 mM sodium vanadate, 2 mM phenylmethylsulfonyl fluoride (PMSF) and 1 mg/ml aprotinin. Lysates were clarified by centrifugation at 10 000 Â g for 15 min. Lysates containing comparable amounts of proteins, estimated by a modified Bradford assay (Bio-Rad, Munchen, Germany), were subjected to Western blot. Immunocomplexes were detected with the enhanced chemiluminescence kit (Amersham Pharmacia Biotech, Little Chalfort, UK). Anti-MAPK (#9101) and anti-phospho-MAPK (#9102) were from New England Biolabs (Beverley, MA, USA). Anti-RET is a polyclonal antibody raised against the tyrosine kinase protein fragment of human RET (Santoro et al., 1995) . AntipY1062 and anti-pY905 are affinity-purified polyclonal antibodies raised against RET peptides containing phosphorylated Y1062 or Y905 (Iwashita et al., 1996; Salvatore et al., 2000; Carlomagno et al., 2003) . Secondary antibodies coupled to horseradish peroxidase were from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
In vitro kinase assay Subconfluent cells transfected with the different RET constructs were solubilized in lysis buffer with phosphatase and protease inhibitors. An aliquot of 50 mg of proteins was immunoprecipitated with anti-RET antibodies; immunocomplexes were recovered with protein A sepharose beads, washed five times with kinase buffer and incubated (20 min at room temperature) in kinase buffer containing 200 mM poly(Lglutamic acid-L-tyrosine) (poly-GT) (Sigma-Aldrich Co, St Louis, MO, USA), 2.5 mCi [g-32 P]ATP and unlabelled ATP to a final concentration of 20 mM in the presence of the inhibitory compound or vehicle. Samples were spotted on Whatman 3MM paper (Springfield Mill, UK) and 32 P incorporation was measured with a b-counter scintillator (Beckman Coulter, Unterschleissheim-Lohhof, Germany).
Growth curves and transformation assay
RAT1 cells (1 Â 10 4 /dish) were seeded on 60-mm dishes in complete medium. The day after (day 1), compounds or vehicle were added to the medium and refreshed every 2 days. Cells were counted every 2 days. For transformation assay, 1 Â 10 5 NIH3T3 fibroblasts were seeded in 10 mm dishes. The day after cells were transfected using the calcium-phosphate precipitation method, as described elsewhere (Santoro et al., 1995) . Transformed foci were scored at 2 weeks. Transforming efficiency was calculated in focus forming units (FFUs) per pmol of added DNA after normalization for the efficiency of colony formation in parallel dishes subjected to marker selection.
